Literature DB >> 26497931

Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.

Vladimir N Podust1, Sibu Balan2, Bee-Cheng Sim2, Michael P Coyle2, Ulrich Ernst2, Robert T Peters3, Volker Schellenberger2.   

Abstract

XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biotherapeutics; Chemical conjugation; Genetic fusion; Half-life extension; Peptides; XTEN protein polymer

Mesh:

Substances:

Year:  2015        PMID: 26497931     DOI: 10.1016/j.jconrel.2015.10.038

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  28 in total

1.  Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery.

Authors:  Samagya Banskota; Parisa Yousefpour; Nadia Kirmani; Xinghai Li; Ashutosh Chilkoti
Journal:  Biomaterials       Date:  2018-11-28       Impact factor: 12.479

2.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

Review 3.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

4.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

Review 5.  Future prospects for noncanonical amino acids in biological therapeutics.

Authors:  Arlinda Rezhdo; Mariha Islam; Manjie Huang; James A Van Deventer
Journal:  Curr Opin Biotechnol       Date:  2019-04-08       Impact factor: 9.740

Review 6.  Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.

Authors:  Sara Busatto; Anthony Pham; Annie Suh; Shane Shapiro; Joy Wolfram
Journal:  Biomed Microdevices       Date:  2019-04-15       Impact factor: 2.838

Review 7.  Recent trends in protein and peptide-based biomaterials for advanced drug delivery.

Authors:  Anastasia Varanko; Soumen Saha; Ashutosh Chilkoti
Journal:  Adv Drug Deliv Rev       Date:  2020-08-29       Impact factor: 15.470

Review 8.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

Review 9.  CAR-T cells: Early successes in blood cancer and challenges in solid tumors.

Authors:  Hassan Dana; Ghanbar Mahmoodi Chalbatani; Seyed Amir Jalali; Hamid Reza Mirzaei; Stephan A Grupp; Eloah Rabello Suarez; Catarina Rapôso; Thomas J Webster
Journal:  Acta Pharm Sin B       Date:  2020-11-02       Impact factor: 11.413

10.  Rational Development of Stable PYY3-36 Peptide Y2 Receptor Agonists.

Authors:  Christian Poulsen; Marie Østergaard Pedersen; Per-Olof Wahlund; Annika Sjölander; Jens Kaalby Thomsen; Kilian W Conde-Frieboes; Johan F Paulsson; Birgitte S Wulff; Søren Østergaard
Journal:  Pharm Res       Date:  2021-07-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.